The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

July 20, 2024

Primary Completion Date

June 23, 2025

Study Completion Date

May 31, 2027

Conditions
Pediatric AsthmaRhinitis, AllergicQuality of Life
Interventions
DRUG

Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis

"1. Subcutaneous Allergen-Specific Immunotherapy:~ * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~ * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~ * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~ * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjing Zhou

OTHER